We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A report from AARP contends that prices for prescription drugs widely used by retirees consistently outpaced inflation between 2006 and 2013, the most recent year for which complete data was available. Read More
Pay-for-delay deals don’t have to be in cash form for them to be at risk of an antitrust suit, according to a recent federal appellate panel ruling. Read More
The FDA and Amarin get another month to settle their differences over the drugmaker’s efforts to promote its cholesterol drug Vascepa off-label. Read More
In a case with broad implications for medical patent protection, the U.S. Supreme Court showed little enthusiasm for lowering a strict appellate standard for enhanced damages during oral arguments Tuesday. Read More
The FDA has accepted Sanofi’s application for expedited review of its once-daily, fixed-dose combination of insulin glargine and GLP-1 receptor agonist lixisenatide for Type 2 diabetes. Read More